Xarelto
(rivaroxaban)

Manufacturer:
Janssen Pharmaceuticals

FDA Approval Date:
July 1, 2011

For treatment of:
Prevention of Deep Vein Thrombosis (DVT)

Dosage:
Oral Tablet

IPC
INDEPENDENT PHARMACEUTICAL CONSULTANTS, INC.

Questions?

annette.bognar@ipc-inc.com
636-614-1344

For more information about IPC and our services:

www.ipc-inc.com

IPC's Recommendation

Implement a Prior Authorization program to ensure Xarelto is used to treat FDA approved conditions, length of therapy restrictions are applied and proper utilization is observed.

Marketing Information from Manufacturer (key points):
The FDA approved Xarelto to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) following total hip replacement or knee replacement surgery.

DVT is a serious medical condition that occurs when a blood clot forms in one of the large veins, usually the lower limbs, leading to either partially or completely blocked circulation. DVT may result in PE if the blood clot travels to the lungs and can result in death if not diagnosed and treated effectively.

Benefits and Concerns:
Xarelto is generally started within 6 to 10 hours after surgery. For hip replacement surgery, the treatment should continue for 35 days. For knee replacement surgery, the treatment should continue for 12 days.

Caution should be used for individuals who have increased risk of hemorrhaging as Xarelto increases the risk of bleeding and can cause serious and fatal bleeding.

This information is being provided for informational purposes only. All decisions about prescription drugs are between the member and his or her physician or other health care provider.